Citations

Mayo Clinic

Showing 10 of 108523 citations.

Natural History of the Iliac Arteries after Endovascular Abdominal Aortic Aneurysm Repair and Suitability of Ectatic Iliac Arteries as a Distal Sealing Zone
Falkensammer, Juergen , Hakaim, Albert G., Oldenburg, W. Andrew, Neuhauser, Beate, Paz‐Fumagalli, Ricardo , McKinney, J. Mark , Hugl, Beate, Klocker, Josef , Biebl, Matthias

Journal of Endovascular Therapy | March 20, 2015 | Volume: 14 | Issue: 5 | Pages: 619-624

10.1177/152660280701400503 | PMID 17924725 Get It

Purpose: To investigate the natural history of dilated common iliac arteries (CIA) exposed to pulsatile blood flow after endovascular abdominal aortic aneurysm repair (EVAR) and the suitability of ectatic iliac arteries as sealing zones using flared iliac limbs. Methods: Follow-up computed tomograms of 102 CIAs in 60 EVAR patients were investigated. Diameter changes in CIAs ≤16 mm (group 1) were compared with changes in vessels where a dilated segment >16 mm in diameter continued to be exposed to pulsatile blood flow (group 2). Within group 2, cases in which the stent terminated proximal to the dilated artery segment (2a) were compared with those that had been treated with a flared limb (2b). Results: The mean CIA diameter increased by 1.0±1.0 mm in group 1 (p<0.001 versus immediately after EVAR) and by 1.5±1.7 mm in group 2 (p<0.001 versus immediately after EVAR) within an average follow-up of 43.6±18.0 months. Diameter increase was more pronounced in dilated CIAs (p=0.048), and it was not significantly different between groups 2a and 2b (p=0.188). No late distal type I endoleak or stent-graft migration associated with CIA ectasia was observed. Conclusion: Dilatation of the CIA is significant after EVAR, and it is more pronounced in ectatic iliac arteries. Although ectatic iliac arteries appear to be suitable sealing zones in the short term, continued follow-up is mandatory.
Impact of Gender on the Outcome of Endovascular Aortic Aneurysm Repair Using the Zenith Stent-Graft: Midterm Results
Hugl, Beate, Hakaim, Albert G., Oldenburg, W. Andrew, McKinney, J. Mark , Nolte, Lorraine A., Greenberg, Roy K., Chuter, Timothy A.M., Biebl, Matthias

Journal of Endovascular Therapy | March 20, 2015 | Volume: 14 | Issue: 2 | Pages: 115-121

10.1177/152660280701400201 | PMID 17484525 Get It

Purpose: To analyze the 2-year outcomes of female patients after endovascular aortic aneurysm repair (EVAR) with the Zenith AAA Endovascular Graft. Methods: A retrospective analysis was conducted of data from the US Zenith multicenter trial and the Zenith female registry on 40 women (10.9%, study group) and 326 men (89.1%, control group) enrolled. All patients had completed their 2-year follow-up. Primary study endpoints were survival, aneurysm rupture, and conversion rate. Significance was assumed if p<0.05. Results: Overall rates of mortality (12.5% for women versus 13.2% for men, p=0.94) and aneurysm rupture (2.5% for women versus 0% for men, p=0.11) were comparable between groups. Conversion to open repair within 2 years was significantly more frequent in women compared to men (7.5% versus 0.6%, p=0.01). The incidence of endoleaks of any type was equivalent between groups at 2 years (13.3% for women versus 6.9% for men, p=0.30). No difference was observed in the need for secondary interventions (15% for women versus 13.5% for men, p=0.81) or aneurysm dilatation >5 mm (10.5% for women versus 2.3% for men, p=0.10). None of the patients developed device migration .10 mm or required intervention for migration. Conclusion: While women underwent conversion to open repair more frequently compared to men at 2 years post EVAR, there was no difference in survival, freedom from aneurysm rupture, or need for secondary interventions between groups. As in men, the Zenith AAA Endovascular Graft provides reliable protection from aneurysm rupture and aneurysm-related death in women in a midterm follow-up.
DNA methylation in lymphoma: an opportunity?
Ansell, Stephen M.

Blood | March 19, 2015 | Volume: 125 | Issue: 12 | Pages: 1848-1849

10.1182/blood-2015-02-625293 | PMID 25792729 Get It

Pilot Development of an Electronic Pediatric Inflammatory Bowel Disease Quiz Game
Grunow, John E., Jacobs, Noel J., Tung, Jeanne

Journal of Pediatric Gastroenterology and Nutrition | March 19, 2015 | Volume: 61 | Issue: 3 | Pages: 292-296

10.1097/mpg.0000000000000788 | PMID 25793902 Get It

AbstractObjectives:Data suggest physicians poorly assess disease‐specific literacy and transition readiness in pediatric patients with inflammatory bowel disease (IBD). We piloted an electronic, interactive iPad quiz game that could be used in a clinical setting, with the aims of measuring IBD‐related knowledge, and concomitant mood and quality of life (QOL) in a pediatric population.Methods:Two pediatric IBD clinics developed and tested 2 versions of “Emma.” Patients between 10 and 18 years of age played Emma during an office visit. Each patient answered 12 randomly selected disease‐related questions and 4 mood‐related questions.Results:Sites 1 and 2 tested Emma v1 between May and August 2013. Emma v2 was tested from November 2013 to January 2014 and from September 2013 to January 2014. A total of 56 patients played Emma v1, whereas 60 played Emma v2. In Emma v2, 73.1% of questions were answered correctly. Patients recognized signs of IBD (88%), causes of diarrhea in addition to IBD (79.4%), and could define lactose intolerance (95.8%), but fewer patients understood serological testing used for disease monitoring (68%) or knew that magnetic resonance enterography did not involve radiation (22.9%). Patients tended to report good functioning in the areas of energy, mood, anxiety, and school‐related QOL. Patients with Crohn disease, however, reported higher stress levels compared with patients with ulcerative colitis; older patients reported lower energy levels, and postsurgical patients reported lower QOL.Conclusions:The Emma iPad game has the potential to evaluate gaps in IBD knowledge, assess emotional functioning, and increase patient engagement as a transition tool in the clinical setting.
Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging
Roberts, Rosebud O., Mielke, Michelle M. , Jack, Clifford R. , Geda, Yonas E. , Rocca, Walter A. , Petersen, Ronald C. , Pankratz, V. Shane , Knopman, David S. , Jack, Clifford R , Mielke, Michelle M , Geda, Yonas E

Neurology | March 18, 2015 | Volume: 84 | Issue: 14 | Pages: 1433-1442

10.1212/wnl.0000000000001437 | PMID 25788555 Get It

A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma
Pal, Sumanta K. , Azad, Arun , Drabkin, Harry A., Costello, Brian A. , Sarantopoulos, John , Kanesvaran, Ravindran , Lauer, Richard C., Starodub, Alexander, Hauke, Ralph J. , Sweeney, Christopher J. , Hahn, Noah M. , Sonpavde, Guru , Richey, Stephen , Breen, T., Kremmidiotis, Gabriel, Leske, Annabell F., Doolin, Elizabeth , Bibby, David C. , Hutson, Thomas E. , Costello, Brian, Bhatia, Shailender , Simpson, Jeremy Andrew , Iglesias, José , Azad, Arun A , Sweeney, Christopher , Hutson, Thomas , Kanesvaran, Ravindran

Clinical Cancer Research | March 18, 2015 | Volume: 21 | Issue: 15 | Pages: 3420-3427

10.1158/1078-0432.ccr-14-3370 | PMID 25788492 Get It

Abstract Purpose: BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with everolimus. In this phase I/II study, efficacy and safety of the combination were explored in patients with metastatic renal cell carcinoma (mRCC). Experimental Design: A phase I study in patients with clear cell mRCC and any prior number of therapies was conducted using a classical 3 + 3 design to evaluate standard doses of everolimus with increasing doses of BNC105P. At the recommended phase II dose (RP2D), patients with clear cell mRCC and one to two prior therapies (including ≥ 1 VEGF-TKI) were randomized to BNC105P with everolimus (arm A) or everolimus alone (arm B). The primary endpoint of the study was 6-month progression-free survival (6MPFS). Secondary endpoints included response rate, PFS, overall survival, and exploratory biomarker analyses. Results: In the phase I study (N = 15), a dose of BNC105P at 16 mg/m2 with everolimus at 10 mg daily was identified as the RP2D. In the phase II study, 139 patients were randomized, with 69 and 67 evaluable patients in arms A and B, respectively. 6MPFS was similar in the treatment arms (arm A: 33.82% vs. arm B: 30.30%, P = 0.66) and no difference in median PFS was observed (arm A: 4.7 mos vs. arm B: 4.1 mos; P = 0.49). Changes in matrix metalloproteinase-9, stem cell factor, sex hormone-binding globulin, and serum amyloid A protein were associated with clinical outcome with BNC105P. Conclusions: Although the primary endpoint was not met in an unselected population, correlative studies suggest several biomarkers that warrant further prospective evaluation. Clin Cancer Res; 21(15); 3420–7. ©2015 AACR.
Sponsors meet scientists to speed pediatric medicines development
Davis, Jonathan M. , Smoyer, William E. , Connor, Edward M., Pastern, Cindy, Purucker, Mary, Schrader, Elisabeth C., Jackson, Cynthia R, Kaskel, Frederick J. , Hirschfeld, Steven , Huskins, W. Charles

Science Translational Medicine | March 18, 2015 | Volume: 7 | Issue: 279 | Pages: No page available

10.1126/scitranslmed.aaa2045 | PMID 25787760 Get It

Child-health research initiative enables rapid response to opportunities for participation in multicenter pediatric clinical trials.
Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma
Psutka, Sarah P. , Leibovich, Bradley C. , Psutka, Sarah P

Therapeutic Advances in Urology | March 18, 2015 | Volume: 7 | Issue: 4 | Pages: 216-229

10.1177/1756287215576443 | PMID 26445601 Get It

The diagnosis of renal cell carcinoma is accompanied by intravascular tumor thrombus in up to 10% of cases, of which nearly one-third of patients also have concurrent metastatic disease. Surgical resection in the form of radical nephrectomy and caval thrombectomy represents the only option to obtain local control of the disease and is associated with durable oncologic control in approximately half of these patients. The objective of this clinical review is to outline the preoperative evaluation for, and operative management of patients with locally advanced renal cell carcinoma with venous tumor thrombi involving the inferior vena cava. Cornerstones of the management of these complex patients include obtaining high-quality imaging to characterize the renal mass and tumor thrombus preoperatively, with further intraoperative real-time evaluation using transesophageal echocardiography, careful surgical planning, and a multidisciplinary approach. Operative management of patients with high-level caval thrombi should be undertaken in high-volume centers by surgical teams with capacity for bypass and invasive intraoperative monitoring. In patients with metastatic disease at presentation, cytoreductive nephrectomy and tumor thrombectomy may be safely performed with simultaneous metastasectomy if possible. In the absence of level one evidence, neoadjuvant targeted therapy should continue to be viewed as experimental and should be employed under the auspices of a clinical trial. However, in patients with significant risk factors for postoperative complications and mortality, and especially in those with metastatic disease, consultation with medical oncology and frontline targeted therapy may be considered.
Surgical treatment of varicose veins and venous malformations in Klippel–Trenaunay syndrome
Malgor, Rafael D. , Gloviczki, Péter , Fahrni, Jennifer , Kalra, Manju , Duncan, Audra A. , Vrtiska, Terri J., Driscoll, David, Vrtiska, Terri, Oderich, Gustavo S. , Gloviczki, Péter

Phlebology: The Journal of Venous Disease | March 18, 2015 | Volume: 31 | Issue: 3 | Pages: 209-215

10.1177/0268355515577322 | PMID 25788406 Get It

Background Klippel–Trenaunay syndrome (KTS) is a mixed mesenchymal malformation characterised by varicose veins, venous and capillary malformations, and hypertrophy of soft tissue and bone. The purpose of this study was to evaluate the surgical outcomes in KTS patients to provide standards for comparison with endovenous therapy. Methods The clinical data of consecutive patient with KTS who underwent open venous surgical treatment between January 1987 and December 2008 were reviewed. Demographics, clinical presentation, operative data, and clinical outcomes were recorded. Follow-up information was obtained from the medical records, mailed questionnaires and phone calls. Descriptive statistics, the Kaplan–Meier method and Log-rank statistics were used where appropriate. Results Twenty-seven females and 22 males, (mean age 26.5 years, range 7.7–55.8) were included in this study. All had varicose veins, 36 (73%) had limb hypertrophy, and 33 (67%) had capillary malformations, with two of three clinical features present in all. The most frequent symptom was pain (N = 43, 88%). Forty-nine patients underwent operations on 53 limbs. Stripping of the GSV, small and accessory saphenous and lateral embryonic veins was performed in 17 (32%), 10 (19%), 9 (17%), and 15 (28%) limbs, respectively. Two patients developed deep vein thrombosis, one had pulmonary embolism (PE), and one patient had peroneal nerve palsy. Freedom from disabling pain at 1, 3 and 5 years was 95%, 77% and 59%, respectively, and freedom from secondary procedures was 78% at 3 years, and 74% at 5 years. At the last follow-up visit, the venous clinical severity score had decreased from 9.48 ± 3.27 to 6.07 ± 3.20 (P < 0.001). Conclusions In selected symptomatic patients with KT syndrome, open surgical treatment is safe and durable. Three-fourths of the patients remain free of disabling pain at five years, but secondary procedures are required in one-fourth of the patients. These data can serve as standards for comparison of endovenous therapy for KT syndrome.
Nelarabine Associated Myotoxicity and Rhabdomyolysis
Haider, Mahnur , Rizvi, Syed Ahsan, Kasi, Pashtoon Murtaza , Rizvi, Syed Ahsan, Kasi, Pashtoon Murtaza

Case Reports in Hematology | March 18, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-4

10.1155/2015/825670 | PMID 25866685 Get It

Nelarabine (ara-G; Arranon; compound 506U78) is an antineoplastic purine analog used for the treatment of refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). The drug was granted accelerated approval in October 2005 by the US Food and Drug Administration (FDA) given the efficacy (induction of complete responses) noted in 2 single-arm trials (one in pediatric setting and one in adult patient population). The main spectra of toxicities that have been reported in these clinical trials and subsequent studies are hematological and neurological. Nelarabine induced rhabdomyolysis and increased creatinine phosphokinase (CK; CPK) levels apparently have been reported and this side effect has been added as an adverse reaction in the product monograph from the drug company during postmarketing surveillance. However, the true extent and incidence of the myotoxicity from the drug are unclear. In this paper we report a grade IV CK elevation and rhabdomyolysis in a patient with T-ALL treated with nelarabine. Given the reported finding, we examined the literature further for myotoxicity, increased CK, and/or rhabdomyolysis associated with the use of the nelarabine and report our findings.